ArticleAntimicrobial agents and chemotherapy2008
Stronger activity of human immunodeficiency virus type 1 protease inhibitors against clinical isolates of Plasmodium vivax than against those of P. falciparum.
Article in Antimicrobial agents and chemotherapy, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 37 citations in OpenAlex.
- Antiretroviral agents and prevention of malaria in HIV-infected Ugandan children.The New England journal of medicine · 2012Trial
- Malaria and HIV/AIDS Coinfection in Patients Under Highly Active Antiretroviral Therapy at the Regional Hospital of Bafoussam (West Cameroon).Journal of parasitology research · 2024Article
- Repurposing Drugs to Fight Hepatic Malaria Parasites.Molecules (Basel, Switzerland) · 2020Review
- The Impact of Antiretroviral Therapy on Malaria Parasite Transmission.Frontiers in microbiology · 2019Article
- Malaria and HIV coinfection in sub-Saharan Africa: prevalence, impact, and treatment strategies.Research and reports in tropical medicine · 2018Review
- Article
- Buy one, get one free? Benefits of certain antiretrovirals against malaria.AIDS (London, England) · 2017Article
- Inhibition ofFrontiers in cellular and infection microbiology · 2017Article
- Diagnosis and Treatment of Plasmodium vivax Malaria.The American journal of tropical medicine and hygiene · 2016Article
- The epidemiological impact of HIV antiretroviral therapy on malaria in children.AIDS (London, England) · 2015Article
- Plasmodium vivax and Plasmodium falciparum ex vivo susceptibility to anti-malarials and gene characterization in Rondônia, West Amazon, Brazil.Malaria journal · 2014Article
- Article
- Transition-state inhibitors of purine salvage and other prospective enzyme targets in malaria.Future medicinal chemistry · 2013Review
- Phenotypic and genotypic characterisation of drug-resistant Plasmodium vivax.Trends in parasitology · 2012Review
- Prevalence and clinical features of HIV and malaria co-infection in hospitalized adults in Beira, Mozambique.Malaria journal · 2012Article
- In vitro activity of antiretroviral drugs against Plasmodium falciparum.Antimicrobial agents and chemotherapy · 2011Article
- Antimalarial effects of human immunodeficiency virus protease inhibitors in rhesus macaques.Antimicrobial agents and chemotherapy · 2011Article
- HIV proteinase inhibitors target the Ddi1-like protein of Leishmania parasites.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2011Article
- The presence of leukocytes in ex vivo assays significantly increases the 50-percent inhibitory concentrations of artesunate and chloroquine against Plasmodium vivax and Plasmodium falciparum.Antimicrobial agents and chemotherapy · 2011Article
- Drugs for malaria: something old, something new, something borrowed.F1000 biology reports · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 6 institutions in 4 countries.
Funding
Abstract
Recent studies using laboratory clones have demonstrated that several antiretroviral protease inhibitors (PIs) inhibit the growth of Plasmodium falciparum at concentrations that may be of clinical significance, especially during human immunodeficiency virus type 1 (HIV-1) and malaria coinfection. Using clinical isolates, we now demonstrate the in vitro effectiveness of two HIV-1 aspartic PIs, saquinavir (SQV) and ritonavir (RTV), against P. vivax (n = 30) and P. falciparum (n = 20) from populations subjected to high levels of mefloquine and artesunate pressure on the Thailand-Myanmar border. The median 50% inhibitory concentration values of P. vivax to RTV and SQV were 2,233 nM (range, 732 to 7,738 nM) and 4,230 nM (range, 1,326 to 8,452 nM), respectively, both within the therapeutic concentration range commonly found for patients treated with these PIs. RTV was fourfold more effective at inhibiting P. vivax than it was at inhibiting P. falciparum, compared to a twofold difference in SQV sensitivity. An increased P. falciparum mdr1 copy number was present in 33% (3/9) of isolates and that of P. vivax mdr1 was present in 9% of isolates (2/22), but neither was associated with PI sensitivity. The inter-Plasmodium sp. variations in PI sensitivity indicate key differences between P. vivax and P. falciparum. PI-containing antiretroviral regimens may demonstrate prophylactic activity against both vivax and falciparum malaria in HIV-infected patients who reside in areas where multidrug-resistant P. vivax or P. falciparum is found.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.